The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies.

The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies, biopharmaceutical company developing drugs for rare diseases and the university spin-off drug developers. To witness the future is most likely greater consolidation through mergers and acquisitions among the large pharmaceutical and small biotech companies. Notes Frost & Sullivan Programme Leader Shabeer Hussain. Lack of investment to bring, new therapies and technologies is a major challenge for small biotech companies.

Is a novel, Phase 3 Clinical Trial Results For Evamist – The first transdermal spray for the treatment of menopausal symptomsVIVUS today announced positive results from the Phase 3 clinical trial with Evamist . ‘ ‘ investigational estradiol metered dose transdermal spray developed for the treatment of vasomotor symptoms of menopause. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Evamist is a novel, once-daily proprietary, first-in – class, transdermal spray that delivers estradiol, a naturally occurring estrogen, for the treatment of hot flashes in women.African-Americans use from histamine2 receptor antagonists , a class of drugs blocks stomach, cognitive impairment cognitive impairment in older African – American adult stomach acids medications associated with cognitive impairment in the elderly. Published Following of Indianapolis University School of Medicine and Regenstrief Institute degree in August issue of the Journal the American Geriatrics Society, the risk to symptoms of cognitive decline being 2.5 times higher for patients who are long this medication..